High-dose short-interval canakinumab therapy for mevalonate kinase deficiency associated with novel MVK variants.

Ilaris (canakinumab) - Novartis

High-dose short-interval canakinumab therapy for mevalonate kinase deficiency associated with novel MVK variants. (PubMed, Rheumatology (Oxford)) - Oct 1, 2026 - No abstract available
Journal

http://www.ncbi.nlm.nih.gov/pubmed/42814885

Daigo Kato; Kanako Mitsunaga; Minako Tomiita; Yoshitake Sato; Yuzaburo Inoue

Oct 1, 2026